On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of ...

In plain language. Written by scientists. For the global HD community.

SKY-0515 is a daily oral drug designed to lower both huntingtin, the protein that drives HD, and PMS1, a DNA repair protein linked to somatic CAG repeat expansion. Researchers hope this dual-target ...

In a recent study, scientists created a chemical that breaks down expanded huntingtin HTT clumps in HD cells and mouse models. This chemical finds HTT clumps and targets them to be broken down or ...

Huntington’s disease (HD) involves the loss of cells in the striatum, an area of the brain that plays important roles in movement, cognition, and behaviour. For decades, researchers have been ...

A recent collaboration between researchers at the University of Leiden and the Huntington Expertise Center Topaz Overduin in the Netherlands has focused on an important yet often overlooked part of ...

Skyhawk Therapeutics has announced by press release new 12-month data from their Phase 1/2 trial of SKY-0515, an experimental oral treatment for Huntington’s disease (HD). The latest results largely ...

A new study shows that lowering a harmful piece of the huntingtin message (Htt1a) appears effective at reducing HD-related symptoms in mice, perhaps more so than targeting full length HTT. Whether ...

When it comes to clearing up the mess created by mutant Huntingtin (HTT) we tend to think of sending external help into the brain, in the form of HTT lowering drugs or anti-sense oligonucleotides ...

When most people picture scientists doing experiments in labs, they imagine mice in mazes or cells growing in petri dishes. But for complex conditions like Huntington’s Disease (HD), these simple ...

On April 30, 2026, uniQure announced that it held a Pre-Submission Meeting with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and plans to file a formal application ...

On April 28th 2026, PTC Therapeutics shared new data from the long-term extension of PIVOT-HD, the Phase 2 clinical trial of votoplam, the daily pill designed to lower huntingtin (HTT) protein in ...